GB Virus C Infection in Patients with Type II Cryoglobulinemia
To the Editor: Misiani and colleagues (1) recently reported a high frequency of GB virus C infection (2) in patients with type II mixed cryoglobulinemia. In 1996, we studied the prevalence of plasma hepatitis G virus (HGV) RNA (a different isolate of GB virus C) (3) in 35 patients who were positive for hepatitis C virus (HCV). Nine patients were men and 26 were women; the mean age ± SD was 66.2 ± 9.0 years. Twenty-three patients had type II and 12 had type III mixed cryoglobulinemia. Twenty patients (9 men and 11 women, with a mean age of 58.8 ± 8.9 years) who had noncryoglobulinemic chronic hepatitis C served as controls. All of the patients with mixed cryoglobulinemia and all controls had histologically proven chronic hepatitis (mean serum alanine aminotransferase levels, 81.1 ± 78.7 U/L [1.35 ± 1.31 jLtkat/L] compared with 112.4 ± 104.3 U/L [1.87 ± 1.74 /xkat/L]; P = 0.2), none had received interferon in the previous 24 months, and none reported any history of blood transfusion or injection drug use.
We detected HGV RNA by reverse transcriptase polymerase chain reaction (PCR) amplification of the NS5 region of the genome and by reverse transcriptase PCR of the putative 5'-noncoding region, as described elsewhere (4) . Plasma HGV RNA was present in one patient with type II mixed cryoglobulinemia (2.9% of all patients and 4.3% of those with type II mixed cryoglobulinemia) and two of the controls (10%). The patient with type II mixed cryoglobulinemia who was positive for HGV RNA was a 72-year-old woman with cirrhosis.
The discordance between our data and the higher prevalence of HGV RNA reported by Misiani and colleagues (1) may have been due to the different sensitivity of HGV and GB virus C detection, which resulted from the amplification of different genomic regions (NS3/helicase for Misiani and colleagues and putative 5'-noncoding region and NS5 in our study), or to differences in the epidemiology of HGV and GB virus C (or their variants) in our patient samples. On the other hand, the cryoglobulinemic syndrome is known to affect mainly women after their fifth decade of life and probably after a long history of chronic HCV infection. Our recent study (4) of the prevalence of HGV RNA in Italian HIV-1-positive drug addicts showed that the prevalence of HGV infection was 23% in the sample as a whole and was higher in patients who had been exposed more recently to parenterally transmitted infection (HIV-1-positive, asymptomatic persons infected with both HIV-1 and HCV type 3a); this suggests that HGV infection is often self-limiting. It is difficult to interpret the significance of the prevalence observed by Misiani and colleagues in a sample of persons with no recent risk for parenterally transmitted infection. Nevertheless, we completely agree with the conclusion of these authors that HGV plays no role in the pathogenesis of mixed cryoglobulinemia.
In response: Zehender and colleagues report on a series of patients in whom the prevalence of HGV infection is much lower than that found in our study. We share their opinion that this discrepancy may be ascribed primarily to the different methods used to detect GB virus C and HGV RNA. Indeed, the high sensitivity of our assay is suggested by the elevated prevalence of GB virus C RNA not only in cryoglobulinemic patients with or without HCV infection but also in anti-HCV-positive blood donors. Furthermore, in another study using the same method, the GB virus C genome was detected in 39% of patients with chronic hepatitis of unknown cause (1) . Unfortunately, reverse transcriptase PCR assays for GB virus C and HGV RNA are generally not well standardized, especially with regard to the amplification of various genomic regions. Thus, large differences in results may be expected.
The possibility that the high prevalence of GB virus C infection in cryoglobulinemic patients reflects widespread circulation of this agent in the general population of our geographic area is unlikely if one considers the low frequency of GB virus C positivity in our blood donors. Another possible explanation of the discrepancy between our results and those of Zehender and colleagues is differences in patient characteristics. First, we studied a more homogenous sample formed only by patients with type II cryoglobulinemia. Second, in contrast to the series reported by Zehender and colleagues, only 33% of our patients had obvious signs of hepatitis; mean alanine aminotransferase values for the group as a whole were 53.2 ± 47.8 U/L (0.89 ± 0.80 jbtkat/L). Finally, we found that 76% of GB virus C RNApositive patients were infected with HCV genotype 2a. Most of our patients (66%), in contrast to data reported in the literature (2), had genotype 2a; thus, the high prevalence of GB virus C infection may be at least partly explained.
Although many epidemiologic and biological characteristics of HGV and GB virus C remain unknown, our study clearly indi- 
CCR5 Genotype and the Clinical Course of HIV-1 Infection
To the Editor: I believe you have done a great disservice to both clinicians and patients by allowing the conclusion in the recent paper by de Roda Husman and colleagues (1) to be published.
The conclusion that "The addition of CCR5 genotype to currently available laboratory markers may allow better estimation of the clinical course of HIV-1 infection" is not supported by the paper. Although the authors are able to suggest again that heterozygosity for the 32-nucleotide deletion in the C-C chemokine receptor 5 gene (CCR5 A32) may be associated with prolonged survival, they give no reason why the test should be ordered. They make no claims of indication for use, clinical benefit, or even clinical importance. Indeed, they note that 12 of their 23 long-term survivors were not CCR5 A32 carriers.
Too often, insupportable claims of clinical relevance are thrown off by authors reviewing one or another correlate of clinical disease. This then becomes the trendy-and extremely expensive-laboratory test du jour, which adds nothing but cost to patient care. A similar case occurred with the HIV-1 genotype resistance assays. No clinically interpretable information is available from these tests, yet hundreds of thousands of dollars of patient funds are being spent on the tests each year and possibly ill-advised therapeutic changes are being made solely on the basis of these widely hyped tests.
Even more interesting is the review by Price and Ridker in the same issue (2) . The authors review the published data and go through an exhaustive discussion about when or if screening for the factor V Leiden mutation should be done. Their review is very useful; the paper and recommendation by de Roda Husman and colleagues are not.
The rapid development of new clinical laboratory tests is very important. However, patients and clinicians are ill served when information on the specific use of the test and interpretation of the result is not available. By allowing de Roda Husman and colleagues to publish a conclusion about the use of CCR5 A32 in HIV-1 infection without specifically outlining who should have the test and how the result should be interpreted, Annals has done a significant disservice to patients and clinicians alike. Currently, neither CCR5 nor HIV-1 genotyping offers useful clinical information. They should be left in the research realm, where appropriate guidelines for their use can be determined through population studies and where their developers should have the responsibility to define data-derived use and interpretation measures before the tests are commercially available. In response: In our study, we examined the predictive value of the CCR5 genotype. The outcome of our analysis was that a wild-type CCR5 genotype increased the relative risk for progression of HIV disease with a factor of 2.5, independent of CD4 + T-lymphocyte counts, T-cell function, HIV-1 biological phenotype, and viral RNA load in serum. As we showed in a cumulative Kaplan-Meier analysis, persons with all markers in a beneficial mode had the longest survival; the persons with the most rapid progression had all markers in a bad mode.
Curtis L. Scribner, MD
Despite these, in our opinion, convincing data, Dr. Scribner claims that our remark that "The addition of CCR5 genotype to currently available laboratory markers may allow better estimation of the clinical course of HIV-1 infection" is not supported by the paper. Although Dr. Scribner appreciates the protective effect of CCR5 A32 heterozygosity in the clinical course of HIV-1 infection, he is disturbed because we have not made any claims about indications for use, clinical benefit, or even clinical importance. In support of his argument, Dr. Scribner mentions, correctly, that 50% of persons classified as long-term survivors in our case-control study had wild-type CCR5 genotype. However, the clinical course of HIV-1 infection is generally accepted to be determined by the interplay of multiple viral, immunologic, and host genetic factors; this is also supported by our cumulative Kaplan-Meier analysis, discussed above. We never intended to suggest that CCR5 genotyping by itself would provide sufficient information. Therefore, we chose the wording of our remark (cited above) carefully.
This, of course, is an academic point of view and does not consider cost-benefit aspects; this is far beyond our expertise. We did not intend to make a statement on whether CCR5 genotyping should be performed as a commercial test or whether it should be further analyzed in the research realm. Although we believe that a more accurate estimate of an HIV-infected person's clinical course and life expectancy would justify any laboratory measurement, we fully underscore the opinion of Dr. Scribner that a proper cost-benefit analysis for each test is essential to keep the costs of medical care within certain limits. 
Coming to Terms with Large Databases
To the Editor: I read with interest the recent editorial by Dr. Laine (1) . Although I applaud Dr. Laine's efforts, as well as those of Drs. Weinberger and Hui in editing the supplement "Measuring Quality and Cost of Care Using Large Databases" (2), I must express my dismay and extreme concern that this information will be used to hurt patients and their physicians. These editors are unwittingly providing yet another way in which managed care organizations, the federal government, and administrators can justify the withholding of funding for patient care, thus driving even more physicians crazy. I do not exaggerate when I write this. I am a rheumatologist in solo private practice in a small city. I have witnessed several physician colleagues suffer physical and mental illnesses that were in large part due to the inestimable stress of trying to serve their patients but also support their families. It is naive for Dr. Laine to write, "Whether large databases will ultimately prove to be as useful or as dangerous as various parties believe remains to be seen." They are already being used to justify the withholding of necessary patient care. Databases, contrary to what the editors say, have almost no usefulness in clinical practice. By that I mean that in the day-to-day business of helping a patient, the physician is in a one-on-one relationship with this patient. He or she is ethically bound to do what he or she truly believes is in the patient's best interest, regardless of published outcomes obtained by using databases, albeit large or small. Perhaps Stephen Jay Gould, in his latest book, Full House, put it best when he wrote "I am not a measure of central tendency.... I am one single human being ... and I want a best assessment of my own changes-for I have personal decisions to make, and my business cannot be dictated by abstract averages" (3) . I agree with Dr. Gould. When I become a patient, I will want my physician to treat me on the basis of my own unique set of signs and symptoms and not on the basis of previously published outcomes that may have biased my clinician's beliefs.
In short, as a practicing physician, I find that using large databases to measure quality outcomes and cost of care is interesting in an academic sense but has no practical benefit in the treatment of the patient in front of me. Whenever another such study is published, it puts more ammunition in the hands of corporate and government forces that seek to destroy compassion and individualized health care in the United States. This is not a prediction of what might happen. It is happening now in physician offices on a daily basis and is both frightening and counterproductive. I realize that databases will continue to be amassed and their contents described. Therefore, they should also come with the following admonition: Warning: These data are to be used for academic purposes only!
Thomas I. Romano, MD, PhD Wheeling, WV 26003
In response: It is unfortunate that Dr. Romano believes that third parties will use information in the Annals supplement to hurt patients and their physicians. Our intent in publishing this supplement was to begin to educate internists about the potential benefits and risks of using large databases to evaluate health care. Dr. Romano fears that managed care organizations, the federal government, and administrators use such data to justify withholding funds for patient care, and they sometimes do. However, research done by using large databases often supports the directing of resources toward certain clinical activities. One such example is given in this issue (1) . By using large databases, McCarthy and colleagues show a clear association between regular use of mammography and diagnosis of early-stage breast cancer. The results of this large database study support spending money on strategies to increase mammography use among older black women rather than withholding resources for care.
Nobody wants their care to be "dictated by abstract averages," but it is safe to say that everyone wants care that is evidencebased. Sometimes the best evidence results from careful analyses of large databases. We hope that the supplement on large databases illustrates the potential strengths of these databases as well as alerting readers to ways in which they might be misused. If Dr. Romano and others truly believe that third parties are using large databases against them and their patients, a good understanding of the pitfalls of large-database research will enable a more successful attack on "the enemy." 
HLA-B27-Associated Cardiac Disease
To the Editor: I read with interest Dr. Bergfeldt's excellent review on the cardiac manifestations of HLA-B27-associated diseases (1). By using selected studies published from 1936 to 1995, the author presented convincing data in support of HLA-B27-associated heart disease as a clinical entity.
The incidence of cardiac manifestations in ankylosing spondylitis is not clear. Transesophageal echocardiography (2) showed increased echogenicity of the subvalvular portion of the interventricular septum in eight of nine men with ankylosing spondylitis. This may represent fibrosis due to inflammation or obliterative endarteritis, possibly extending from the aortic valve. Asymptomatic cardiac involvement may therefore be common in ankylosing spondylitis. Transesophageal echocardiography could be used as a sensitive research tool to evaluate the development and progression of cardiac disease in ankylosing spondylitis, even in the absence of symptoms.
Ion A. Arnason, MD UW Health, Portage Community Clinic Portage, WI 53901
In response: I appreciate Dr. Arnason's letter and his suggestion that transesophageal echocardiography may be more sensitive than transthoracic echocardiography for evaluating cardiac manifestations related to the HLA-B27-associated disease process. The increased sensitivity is analogous to what has been proven for bacterial endocarditis. In the hands of Dr. Arnason and his colleagues, the transesophageal echocardiography-derived observations regarding the subaortic structures also seemed to be specific for patients with ankylosing spondylitis (1) . If these results can be confirmed and extended, they may also expand the proportion of HLA-B27-positive patients with disease manifestations related to this genetic trait beyond the present figure of 20% to 25%.
I would, however, like to stress the fact that transesophageal echocardiography is still a "research tool" for this indication. Much work, such as longitudinal studies, needs to be done to prove the clinical value of repeated evaluations with this test, which was performed in only a minority of Arnason and colleagues' cohort of patients with ankylosing spondylitis.
For pathophysiologic reasons discussed in my review, I doubt that Arnason and colleagues' observations will have any predictive value with regard to the development of aortic valve insufficiency or atrioventricular conduction block.
Lennart Bergfeldt, MD, PhD
Karolinska Hospital S-171 76 Stockholm, Sweden 
Granulomatous Disease in Common Variable Immunodeficiency
To the Editor: Mechanic and colleagues described 17 hypogammaglobulinemic patients with common variable immunodeficiency who had a granulomatous disease (1). They found that 16 of 17 patients had deficient T-cell proliferation to mitogens, a finding suggesting that impaired T-cell function may lead to the abnormal sequestration of antigen and the subsequent formation of granulomas. In this regard, the analysis of the yd T cells, which are classically CD4~ CD8" double-negative and whose involvement in granulomatous disease has already been shown (2), could be informative.
As an example, we describe a 31-year-old woman in whom common variable immunodeficiency was diagnosed in April 1995. The patient was seen in July 1996 reporting recent weight loss and a 2-year history of chronic diarrhea. Clinical investigations disclosed a steatorrhea and protein-losing enteropathy. Computed tomography of the abdomen showed mesenteric and retroperitoneal masses, interpreted as necrosed lymphadenopathies. Histologic examination of lymphadenopathy biopsy specimens showed epithelioid cell granulomas with polynucleated giant cells without caseous necrosis. Smears stained with Ziehl-Neelsen were positive for acid-fast bacilli, whereas culture and polymerase chain reaction remained negative for tuberculous and nontuberculous mycobacteria. Thus, the diagnosis of mycobacterial infection was never confirmed.
The patient was lymphopenic (lympocyte count, 364 cells/ mm 3 ), and the T-cell subsets, determined by flow cytometry (3) (3) . Antimycobacterial therapy against tuberculous and nontuberculous mycobacteria was begun, with a poor clinical result. After 9 months of treatment, lymphadenopathy persisted and the percentage of double-negative T cells had not decreased (35%).
In view of studies describing in vivo and in vitro activation of y8 cells by microorganisms (3-5), we suggest that yd T cells are of clinical interest because their expansion may be viewed as a way to alleviate the impaired T-cell-mediated immunity in patients with common variable deficiency in whom the cause of granulomas remains elusive. To the Editor: Mechanic and colleagues' report on granulomatous disease in common variable immunodeficiency (1) described one patient with primary biliary cirrhosis. To our knowledge, this pairing has not been previously reported. We have been following a woman who was found to have both disorders at age 72 years. She had been experiencing repeated pulmonary infections for 7 years. By 1995, her IgG level was 40 mg/dL and her IgA level was 50 mg/dL. The IgM level was increased to 368 mg/dL with a small IgM K monoclonal spike. The absolute lymphocyte count was only 672 cells/mm 3 
Jean-Francois
Because of persistently elevated alkaline phosphatase levels (maximum, 250 U/L) and mild increases in alanine aminotransferase and aspartate aminotransferase levels, liver biopsy was performed. Examination of the specimen showed primary biliary cirrhosis. Antimitochondrial antibody of the IgM class was present at a titer of 1:2560. Ursodiol, 600 mg/d over the next 18 months, resulted in normalization of the alkaline phosphatase and liver enzyme levels. The antimitochondrial antibody titer decreased to 1:40.
Despite profound reductions in T and B cells, the patient was capable of mounting a specific antibody response to mitochondrial antigen. For most patients with only primary biliary cirrhosis, the titer remains elevated despite therapy. It is impossible to know whether gammaglobulin, ursodiol, or both therapies have contributed to the reduction of the antibody titer. It is also possible that the decrease in the titer reflected the instability of an immune response in a patient with common variable immunodeficiency. Normalization of the liver enzyme levels, however, indicates improvement in liver pathology. We concur that it is important to diagnose hypogammaglobulinemia because of the possibility that it contributes to the injurious granulomatous changes. In response: Viallard and colleagues describe an unusual case of extensive granulomatous disease in a woman with common variable immunodeficiency who had a large number of peripheral double-negative CD3 + T cells that displayed the yd phenotype and had a skewed variable gene segment usage. These authors suggest that the expansion of yd T cells could be viewed as a deviation brought about in compensation for the impaired T-cell immunity. Although the search for mycobacteria was not ultimately rewarded, it remains possible that a specific microbial species was responsible for this unusual T-cell expansion. Katial and colleagues (1) described a patient with common variable immunodeficiency who had a prominent expansion of peripheral blood yd T cells and an inverted ratio of CD4 to CD8 T cells in association with unexplained fever and pulmonary infiltrates. Granulomatous lesions were not identified in this case, but an immune-driven expansion of yd cells was also suggested. Nilssen and colleagues (2) found increased numbers of CD3 + T cells expressing the yd T-cell receptor in the intestinal tract of persons with common variable immunodeficiency and other B-cell defects, especially those with villous atrophy. An interesting aspect of Viallard and colleagues' case is the presence of prominent intestinal tract disease.
N. Peter Zauber, MD
Zauber and coworkers describe a patient who, like one of our patients, had primary biliary cirrhosis with common variable immunodeficiency. We had previously reported one other case of biopsy-proven primary biliary cirrhosis in a woman with common variable immunodeficiency (3). This woman was 61 years of age at presentation and had chronic pruritis, hepatomegaly, ascites, and peripheral edema. She died of coronary artery disease at age 63 years.
Since then, we have also seen a second patient: a 35-year-old man who had a history of Hodgkin disease, stage IV-B, that was treated with chemotherapy when the patient was 25 years of age. At age 29 years, abnormal liver function test results, present during chemotherapy, were investigated; liver biopsy confirmed primary biliary cirrhosis. The patient was positive for antimitochondrial antibodies (titer, 1:160) and began receiving ursodiol.
Two years later, immunoglobulin levels, which had been reduced for at least 8 years, were retested. The IgG level was 253 mg/dL, the IgA level was 22 mg/dL, and the IgM level was 72 mg/dL. Intravenous immunoglobulin therapy was started, and chronic bronchial and sinus infections improved. As was seen with the patient described by Zauber and colleagues, the antimitochondrial antibody titer decreased to 1:40 after intravenous immunoglobulin therapy began. Two years later, because of continued liver dysfunction and worsened liver histologic findings, methotrexate therapy, 15 mg/wk, was started. Two years after this therapy began, the patient developed sudden-onset pulmonary infiltrates and sensory changes; B-cell lymphoma involving the lungs and central nervous system was diagnosed. He died after autologous bone marrow transplantation. After our Annals report appeared, Mulligan and colleagues (4) reported that an uncommon tumor necrosis factor allele was more likely to be found in patients with common variable immunodeficiency who have granulomatous disease, suggesting a potential genetic mechanism for this phenotype. Because this phenotype seems to be associated with autoimmunity and tissue damage, its recognition is important. 
Charlotte Cunningham-Rundles

Numeracy
To the Editor: In their recent article, Schwartz and colleagues (1) raise the important issue of whether patients have sufficient quantitative reasoning ability to understand risk-benefit information about mammography. They show that women's ability to gauge their risks for breast cancer and potential benefit from mammography correlates with greater numeracy, as measured by a three-item questionnaire. It is hard to overstate the importance of this finding because it has profound implications for clinical practice and for our understanding of informed consent in this and other settings. The authors' findings lead naturally to another, even more disturbing question: How "numerate" are physicians? Just as patients may be unable to assess quantitative information, physicians may not be able to present information clearly and accurately. Has this been investigated? Are there measured differences between the numerical skills of internists, family practitioners, and gynecologists? If we as a population are failing to effectively present quantitative information to our patients, then it is imperative that we recognize and remedy that failure.
Robert D. Blank, MD, PhD
The Hospital for Special Surgery New York, NY 10021
In response: We are pleased by Dr. Blank's interest in our study. We agree that the issue of physician numeracy merits attention. We do not know of any studies specifically assessing physician's facility with numbers or ability to communicate quantitative information about disease risk or treatment benefit. Although higher levels of educational attainment are related to better quantitative ability (1), even highly educated people may have difficulty with basic numerical concepts. In our study, for example, only 10 of 31 women with postgraduate degrees answered all three numeracy questions correctly. In the National Adult Literacy Survey, 11% of respondents who reported graduate degrees scored in the two lowest quintiles of quantitative literacy. Although research has focused on other aspects of physician-patient communication, evaluation of the effectiveness of communication of probabilistic information is an important area for future work. 
Lisa M. Schwartz, MD, MS Steven Woloshin, MD, MS
Tacrolimus To Treat Pyoderma Gangrenosum Resistant to Cyclosporine
To the Editor: Steroids and, recently, cyclosporine, are effective in the treatment of most pyodermic lesions (1). Tacrolimus, a new immunosuppressive drug, inhibits T-cell activation by blocking receptor-mediated signal transduction pathways (2, 3) .
A 30-year-old man developed ileocolonic Crohn disease complicated by perianal fistula in 1984. After two ileal resections, he received maintenance therapy with sulfasalazine (4 g/d) until May 1996, when steroid therapy was started for a clinical relapse. On 25 July 1996, the patient noted diarrhea with purulent discharge from his perianal fistula and developed painful swelling and a synovial effusion of the right knee. Soon after, a 5-cm painful pustula appeared on the pretibial area. The cutaneous lesion ulcerated; produced a purulent, necrotic discharge, and had deep purple, undermined edges. Cultures of the lesion were negative.
Therapy with intravenous cyclosporine (4 mg/kg of body weight per day) was started. This was changed to oral therapy at 1 week, and the blood level of the agent was maintained between 150 and 350 ng/mL. The pyodermic lesion partly re-epithelialized in 10 days, and the patient's clinical condition steadily improved and remained stable for the following month.
On 15 October 1996, the patient was readmitted with fever (body temperature, 38 °C); severe pain in the left leg; and a 15-cm area of necrotic, purulent discharge at the site of the previous lesion, which was surrounded by multiple small, purple, satellite pustulae. Despite a combination of cyclosporine and systemic antibiotics, the ulcerative lesion deepened and spread over the whole circumference of the leg. On 26 October 1996, oral therapy with tacrolimus (0.1 mg/kg per day) was started. Within a few days, wide areas of granulation tissue became evident, and re-epithelialization was complete in 1 month. Tacrolimus therapy was discontinued in March 1997, and the patient remains in remission with azathioprine maintenance therapy alone after 10 months.
Tacrolimus can effectively and safely treat highly destructive cyclosporine-resistant pyoderma gangrenosum. 
Avoidance of Tick-Borne Diseases
To the Editor: Lyme disease is caused by the spirochete Borrelia burgdorferi, which is transmitted via a bite from the tick Ixodes scapularis. White-footed mice, which are hosts for the tick, are responsible for transmitting the organism causing Lyme disease (1-3). Current recommendations to wear long sleeves and tuck one's pants into socks, in the hope of reducing exposure to ticks, are rarely followed (4). More practical methods are needed.
To test the hypothesis that ticks are most likely to be found in areas supportive of mice, we performed several experiments. Among survival requirements for mice, a key variable is ground cover for protection; open space is dangerous (5) . Pairs of investigators, training in a wilderness survival school, randomly chose and explored different 10-square-yard areas in the woods during nymphal tick season for signs of mice (bedding, hairs, track imprints, chew marks, feeding, area, and scat) (5). On the basis of coverage, areas were independently classified as presenting putatively high, intermediate, and low suitability or risk. At first glance, the areas appeared similar. High suitability was defined by coverage greater than 3 inches high and bare ground that was not readily visible. Low suitability was defined by coverage less than 1 inch high and bare-ground spots.
After 2 hours of potential exposure, clothing and body checks and counts for Ixodes ticks were performed. The data are summarized in the Table. An average of 4.4 ticks per person were found on persons exposed in the high-suitability areas compared with 0.2 ticks per person in low-suitability areas {P < 0.01). This indicates that the risk for exposure is 22 times greater in the high-suitability areas than in the low suitability areas. Evidence of mouse habitation was most notable in the well-covered areas.
Awareness, recognition, and avoidance of these high-risk areas may markedly reduce the risk for exposure to Lyme and other tick-borne infections (3). 
More on the Most Terrible of the Ministers of Death
To the Editor: I would like to add a historical footnote to Barquet and Domingo's concise history of smallpox (1) . In 1803, Thomas Jefferson outlined his plans for Meriwether Lewis's exploration of the Louisiana Purchase and western continent. Wellversed in the value of the kine-pox (cow pox) vaccination, Jefferson advised, "Carry with you some matter of the kine-pox; inform those of them with whom you may be, of its efficacy as a preservative from smallpox; & instruct & encourage them in the use of it. This may be especially done wherever you winter" (2) .
Lewis intended to follow this prescription, but in a communication to the president in October 1803 he asked for a reorder of cowpox vaccine: "I would thank you for forward[ing] me some of the Vaxine matter, as I have reason to believe from several experiments made with what I have, that it has lost its virtue" (2) . Additional vaccine material was never received.
During the winter of 1804-1805, Lewis and Clark camped near several Mandan and Hidatsa villages on the banks of the Missouri River. They learned that these Indian tribes, like many others, had been devastated by previous smallpox epidemics. Thirty-two years later, another smallpox epidemic with a 90% mortality rate would befall the same tribes who had been deprived of the benefit of Jefferson's kine-pox vaccine.
History is replete with "ifs." If Lewis's "kine-pox matter" had maintained its virtue, if Lewis could have propagated it and vaccinated the people where he wintered, if these native people would have accepted Lewis's "medicine" and adopted the vaccination methods, then Jefferson's vision of safeguarding the nonimmune native population from the ravages of smallpox would have been realized for the Mandan and Hidasta people and perhaps other Indian nations.
Ronald V. Loge, MD Dillon, MT 59725
To the Editor: Barquet and Domingo (1) present an enthralling history of the smallpox virus but end their article with a regrettably incomplete summary of the recent scientific debate over the destruction of variola. Since the time of the most recent stay of execution of the virus in early 1996, some of the rich scientific and medical value of variola has come to light. Indeed, in the past few years, tantalizing bits of understanding of the unique propensity of the virus to induce immune tolerance or immunosuppression by way of cytokine inhibition (2) and of the structure-function relations of the genome (3) have been determined. That these properties have now been related to protein products of the virus is perhaps unsurprising given Barquet and Domingo's observation that many strains of the virus cause disease with extraordinarily high penetrance in a given population. However, the previously elusive mechanisms of action, including interference with MHC-restricted antigen presentation, strongly suggest novel models of immune modulation of relevance to other immunosuppressive agents, and the potential for exploitation for important clinical application, such as organ transplantation (4). Ironically, this "most terrible of the ministers of death" may hold the key to selective inhibition of primary immune system re-sponses, advancing us toward immunosuppressive regimens far less toxic to patients.
Proponents of destruction state that cloning of variola provides an adequate store of genetic material for later study. Although cell biologists have learned much from atomizing their targets, all virologists know that smashing a watch to bits does present a daunting obstacle to learning all of its integrated functionality. Immune system manipulation using the hitherto-disparaged virus requires retention of the entirety of the genome (5) or of pieces that can easily be fully reconstituted. Elimination of the virus is not only political folly; recent literature demonstrates that squandering this immensely valuable resource is scientifically imprudent at this stage of our knowledge.
In response: The anecdote provided by Dr. Loge documents Jefferson's extraordinary concern for the scientific advances of his time and for public health. In contrast to the lack of interest shown by his predecessor, John Adams, Jefferson tried to diffuse smallpox vaccine to indigenous U.S. populations (1).
We do not question the historical importance of the event narrated by Dr. Loge, but as he himself recognizes, history is full of "ifs." If the circumstances of Lewis's expedition had been more favorable as far as the vaccine is concerned, the result would undoubtedly have been an important historical episode, comparable to Charles IV of Spain's Vaccine Expedition (2). Unfortunately, this was not the case. We believe that the relationship among Lewis, the expedition to explore Lousiana, and the smallpox vaccine, although historically important, is merely an anecdote from the point of view of the fight against smallpox. Edward Jenner himself sent the Abenakis a book that explained the art of vaccination (3). The first official action against smallpox occurred in 1832, when the U.S. Congress allocated $12 000 to ensure the vaccination of the Native Americans (3). This occurred 2 years after President Andrew Jackson (who had smallpox at 14 years of age) initiated a massive resettlement of Indians from the east to the west of the country (3). The effectiveness of these measures was dubious because from 1836 to 1840, a pandemic lead to the practical disappearance of the Omaha, Oto, Missouri, and Mandan tribes (3).
We do not agree with Dr. Zelicoff that the final part of our article on the history of smallpox, and not on the history of the smallpox virus, is incomplete. Our objective was to reveal the polemic generated by the possible destruction of the smallpox virus. We agree that enormous knowledge on the selective inhibition of primary immune system responses may emerge from the study of the smallpox virus. The final decision should be based on consensus of the scientific community, which should first and foremost remember that never again should a human being die of smallpox. The opinion of those (like Dr. Zelicoff) who think that the benefits of conservation of the virus are greater than those of its destruction should be considered, but so should the opinion of those who believe that maintaining the smallpox virus, even with the greatest security measures possible, involves a potential threat (4, 5) that a species as unpredictable as the human race should not have within its grasp.
Nicolau Barquet, MD
Pere Domingo, MD Autonomous University of Barcelona Barcelona, Spain to call her internist at home that there was some degree of friendship or at least a more than passing social acquaintance. It is my own impression and opinion that this type of relationship can deleteriously affect professional judgment. I believe that this largely has to do with one's formed conceptions about the coping styles and psychological makeup of friends and acquaintances. Such conceptions are not necessarily conducive to a professional relationship, the nature of which presumes a degree of detachment or separation from the personal and social lives of patients.
I am also concerned by the willingness of the Editor to publish this essay. Specifically, did the Editor obtain independent verification of the events described or obtain the perspective of the maligned internist? As department chair of a 15-provider internal medicine division of a multispeciality group, I am required to review patient complaints. Many of these are similar to Ms. Bingham's. Often, the physician's version is significantly at odds with the patient's. Ms. Bingham, as the spouse of a former representative to the U.S. Congress, has a high profile in her community. The section of the Bronx (known to most who live there as Riverdale) in which Ms. Bingham lives is disproportionately populated by physicians, many of whom are affiliated with academic centers in New York. It seems likely that the identity of the maligned physician would be known to many in the lay and professional communities. I would hope that the Editor performed the appropriate investigation and "fact checking" before allowing this physician's reputation to be denigrated in such a widely circulated professional forum. To the Editor: My perspective is that of a general internist in private practice for the past 18 years who has no academic or administrative ties. What merits does this experience have for Annals'? I raise a few questions to place Ms. Bingham's anecdote (1) in proper perspective before we strike out her general internist.
Douglas G. MacDonald, MD
Was the author's general internist on call when she called him at home on that Saturday? If he wasn't, she should have called the internist covering for her physician that weekend. Why the author had the physician's home number is unknown; the subsequent events provide a good reason not to give one's home number to patients. If the author's general internist was on call, then his not returning her call (strike 1) is unpardonable and her grievance begins to take on credibility. What would have been her reaction if he had called her back and told her to call the physician covering for him that weekend?
When Ms. Bingham initially called her physician, he should have told her to come to his office, where he could further discuss her symptoms, examine her, and make a decision and recommendation about her symptoms. A telephone consultation for a diagnosis with recommendations just doesn't cut it these days. Doing so shows a lack of interest and questionable medical judgment (strike 2), especially because the author seems to be a noncomplainer with a new problem. She probably wasn't charged for this telephone consultation, and the adage describing the results of such free advice may be applicable here.
The fact that the author's original general internist didn't visit when she was in the hospital (strike 3) is the final straw that broke this previously long-standing relationship.
I am neither condoning nor condemning Ms. Bingham's general internist. One could make the case that her physician struck out, but additional questions need to be answered before we send him back to the dugout. For example, why did the author order reprints? Does she plan to send them to all her friends with the name of the physician? She could have written a letter to her general internist about her complaints, but publishing her experience should satisfy her therapeutic rage. To the Editor: June Bingham's heartfelt anecdote (1) makes worthy reading for any practitioner. It does, however, raise several inadequately explored issues.
S.G. Cassiere, MD
If one accepts the author's description of her internist as a "good doctor," it is highly unlikely that he willfully made an incorrect diagnosis initially. He lacked either knowledge or sufficient information. In either event, as a good physician, he would appreciate feedback on his error so that he may learn and improve his diagnostic acumen for future use. Otherwise, this is a lost opportunity for him and his other patients.
In a similar vein, did his teenager actually deliver the telephone message on that fateful weekend? Maybe he is still unaware that Ms. Bingham called. Did his physician-wife relay to him the information on Ms. Bingham's hospitalization? If the internist was (or still is) unaware, then the issues are different from those portrayed. If he was aware, was he now too embarrassed to call the patient in follow-up? And, if so, shouldn't this flaw be raised with him so that it can be averted in future dealings with other patients?
Without investigating the circumstances and without talking to the physician, it is impossible to determine how a "good doctor" would allow this to happen. It is a disservice to him and his other patients not to discuss these events with him in an effort to convert a negative interaction, with a near brush with death, into a more constructive use of a perceived poor process. It would be a waste of a perceptive patient's observations and concerns if the internist were not made aware of them. In response: Drs. Sklaver, MacDonald, Cassiere, and Matz raise several valid points pertaining to the piece by Ms. Bingham. First, to Dr. MacDonald's central question: Is the story true? To our satisfaction, the answer is "yes." In the patient's initial telephone encounter with her internist, she is told to call a neurologist. That could hardly have been fabricated. As a response from her physician, it is unacceptable, as Dr. Cassiere rightly points out.
Robert Matz, MD
Second, Dr. Sklaver asks whether any of Ms. Bingham's demands are unrealistic. Perhaps. She certainly has a right to a quick and accurate diagnosis when giving such a history. Beyond that, perhaps her expectations were too high. But she was seriously ill, desperate, and, thankfully, determined to get help. This was a patient who fell through the cracks. It happens to the best of us. We must never blame the victim.
Dr. MacDonald is concerned that the identity of the internist may be determined. It is certainly not immediately apparent. Yet with a fair amount of detective work, his identity could be known. But why would anyone bother when similar stories could be told of many of us?
Finally, Dr. Matz worries that the internist will not be informed, and Drs. Sklaver and MacDonald question our reasons for publishing Ms. Bingham's piece. If the story is essentially true, as we believe it is, then it is a poignant example of missed opportunity. We have all been there, more than any of us would want to admit. Rather than blaming one internist, we are attempting, through this and other "On Being A Patient" pieces, to inform us all. It's a reminder we all can use.
Michael A. LaCombe, MD Associate Editor
Federated Council of Internal Medicine's Resource Guide for Residency Education
To the Editor: The publication of the Federated Council of Internal Medicine's resource guide to curriculum development (1) is an exciting event. This guide should achieve unity across all training programs while still allowing for individual variations. My colleagues and I recently revised the curriculum at our institution and, after long discussions, decided to add two areas of competency. One is alternative and complementary medicine, in which the residents will learn about classification (as developed by the Office of Alternative Medicine of the National Institutes of Health); possible interaction between alternative medicine and allopathic medicine; and, more important, where to find reliable information. The addition was considered necessary given the increasing number of patients using complementary therapies (2) and the potentially serious interactions between prescription medications and "natural" remedies. The second addition was a list of suggested literary and artistic works that in our mind will improve the humanistic qualities and the life-long learning skills of the "doctors for adults" that we train (3).
